Changing the future of Oncology.
Clinical/Scientific Presentation and Publication Highlights
Sutro Biopharma Presents at World ADC 2020 – PowerPoint Presentation
To download the World ADC presentation by Arturo Molina, MD, MS, Chief Medical Officer, CLICK HERE To download the World ADC presentation by Trevor Hallam, Ph.D., Chief Scientific Officer, CLICK HERE To download the World ADC presentation by Shabbir Anik, Ph.D.,...
Cantor Fitzgerald Virtual Heathcare Conference 2020 – PowerPoint Presentation
To download the presentation, Click Here
International Gynecologic Cancer Society (IGCS) Virtual Healthcare Conference 2020 – Poster
Phase 1 Dose-Escalation Study of STRO-002, An Anti-Folate Receptor Alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC)
Investor Conference Call September 9, 2020 – Presentation
To download the presentation, Click Here
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
Updated Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Today Scheduled for 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 – Sutro...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Scheduled for Sept 9, 2020 at 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020...
IGCS 2020 Annual Global Meeting – Abstract
Phase 1 Dose-Escalation Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum Resistant/Refractory Epithelial Ovarian Cancer (OC). Dr. Naumann is currently the Director of Minimally Invasive Surgery in...
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., August 10, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Bristol Myers Squibb Investor Series
June 25, 2020 at 11:30am ET WEBCAST View This Presentation June 22, 2020 at 11:30am ET WEBCAST View This Presentation